TABLE. Estimated percentage* of persons infected with SARS-CoV-2 for the first time among blood donors, by analysis quarter, sociodemographic characteristics, and vaccination status — United States, April 2021–September 2022.
| Characteristic | Period, % (95% CI) |
||
|---|---|---|---|
| Apr–Jun 2021 to Jan–Mar 2022 | Jan–Mar 2022 to Apr–Jun 2022 | Apr–Jun 2022 to Jul–Sep 2022 | |
|
Overall
| |||
|
Total
|
42.5 (41.8–43.3)
|
14.5 (13.7–15.3)
|
23.6 (22.8–24.5)
|
| Unvaccinated |
67.0 (65.6–68.4)† |
21.7 (19.1–24.4)† |
28.3 (25.5–31.3)† |
| Vaccinated |
26.3 (25.4–27.1) |
13.3 (12.4–14.1) |
22.9 (22.1–23.8) |
|
Age group, yrs
| |||
|
16–29
| |||
|
Total
|
57.4 (54.8–59.9)
|
21.8 (18.6–25.4)
|
29.3 (25.8–33.0)
|
| Unvaccinated |
73.8 (69.5–77.7) |
31.5 (21.5–43.7) |
29.5 (18.1–44.2) |
| Vaccinated |
41.2 (38.1–44.4) |
19.7 (16.6–23.3) |
29.2 (25.6–33.1) |
|
30–49
| |||
|
Total
|
51.8 (50.4–53.3)
|
18.0 (16.1–20.0)
|
26.8 (24.9–28.8)
|
| Unvaccinated |
70.6 (68.5–72.5) |
23.0 (17.9–28.9) |
25.6 (21.3–30.4) |
| Vaccinated |
32.5 (30.6–34.4) |
16.9 (15.0–18.9) |
27.0 (25.0–29.2) |
|
50–64
| |||
|
Total
|
38.9 (37.3–40.5)
|
13.2 (12.0–14.6)
|
24.1 (22.4–25.9)
|
| Unvaccinated |
61.5 (58.5–64.4) |
19.8 (16.0–24.2) |
32.0 (27.5–36.9) |
| Vaccinated |
24.6 (23.1–26.3) |
12.1 (10.8–13.6) |
22.9 (21.2–24.7) |
|
≥65
| |||
|
Total
|
21.0 (20.0–22.2)
|
9.2 (8.4–10.0)
|
18.5 (17.4–19.7)
|
| Unvaccinated |
49.6 (46.3–52.9) |
13.7 (11.3–16.5) |
27.0 (22.8–31.6) |
| Vaccinated |
15.0 (13.9–16.2) |
8.7 (7.9–9.6) |
17.8 (16.6–19.0) |
|
Race and ethnicity§
| |||
|
Asian
| |||
|
Total
|
29.1 (26.0–32.3)
|
8.9 (6.6–11.8)
|
23.2 (19.5–27.5)
|
| Unvaccinated |
53.1 (40.7–65.0) |
6.3 (1.9–18.8) |
22.1 (8.3–47.0) |
| Vaccinated |
24.7 (21.7–27.9) |
9.0 (6.7–12.1) |
23.3 (19.5–27.5) |
|
Black or African American
| |||
|
Total
|
42.4 (37.8–47.2)
|
12.9 (9.5–17.4)
|
23.7 (19.4–28.6)
|
| Unvaccinated |
71.6 (61.0–80.3) |
14.8 (3.0–49.5) |
21.7 (5.0–59.3) |
| Vaccinated |
30.1 (25.9–34.6) |
12.8 (9.3–17.3) |
23.9 (19.7–28.6) |
|
White
| |||
|
Total
|
43.2 (42.4–43.9)
|
15.3 (14.6–16.1)
|
23.5 (22.8–24.3)
|
| Unvaccinated |
67.4 (66.0–68.8) |
22.7 (20.1–25.6) |
29.5 (26.6–32.5) |
| Vaccinated |
23.5 (22.9–24.1) |
13.8 (13.1–14.6) |
22.5 (21.7–23.3) |
|
Hispanic or Latino
| |||
|
Total
|
45.5 (42.9–48.2)
|
14.0 (11.8–16.4)
|
23.4 (20.9–26.1)
|
| Unvaccinated |
64.6 (59.9–69.1) |
17.9 (12.2–25.4) |
27.2 (18.7–37.9) |
| Vaccinated |
34.5 (31.6–37.5) |
13.3 (11.0–16.1) |
22.8 (20.3–25.6) |
|
Other and multiple races¶
| |||
|
Total
|
43.4 (38.3–48.7)
|
18.1 (12.7–25.2)
|
27.3 (21.9–33.6)
|
| Unvaccinated |
65.7 (56.5–73.9) |
33.4 (15.1–58.7) |
21.6 (9.9–40.8) |
| Vaccinated | 28.1 (22.8–34.0) | 14.7 (10.4–20.4) | 28.3 (22.3–35.2) |
* Percentage of uninfected persons (anti-nucleocapsid–negative in the previous 3-month period) seroconverting to anti-nucleocapsid–positive. If both vaccination and infection occurred between donations included in the study, the order could not be determined, and some unvaccinated donors might have been vaccinated before infection and thus misclassified.
† If donors who transitioned from no antibodies to hybrid immunity between April–June 2021 and January–March 2022 were excluded, an estimated 55.5% (95% CI = 53.9%–57.1%) of unvaccinated donors were infected. For other periods, exclusion did not substantially change results. Between January–March and April–June 2022, 0.4% of persons shifted from no antibodies to hybrid immunity. Between April–June and July–September 2022, 0.3% of persons shifted from no antibodies to hybrid immunity.
§ Persons of Hispanic or Latino (Hispanic) origin might be of any race but are categorized as Hispanic; all racial groups are non-Hispanic.
¶ Includes American Indian or Alaska Native and non-Hispanic persons of other races.